The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 17, 2015
Filed:
Aug. 17, 2012
Gerard Griffioen, Linden, BE;
Giuseppe Cecere, Basel, CH;
Matthias Nettekoven, Grenzach-Wyhlen, DE;
Katrien Princen, Heverlee, BE;
Hasane Ratni, Habsheim, FR;
Mark Rogers-evans, Bottmingen, CH;
Walter Vifian, Gelterkinden, CH;
Gerard Griffioen, Linden, BE;
Giuseppe Cecere, Basel, CH;
Matthias Nettekoven, Grenzach-Wyhlen, DE;
Katrien Princen, Heverlee, BE;
Hasane Ratni, Habsheim, FR;
Mark Rogers-Evans, Bottmingen, CH;
Walter Vifian, Gelterkinden, CH;
REMYND NV, Leuven, BE;
Abstract
The present invention relates to a compound of formula (IA), wherein Gis lower alkyl; lower alkyl substituted by one or more halogens; cycloalkyl; tetrahydropyran-4-yl; phenethyl; phenethyl substituted by one or more halogens; phenoxymethyl; phenoxymethyl substituted by one or more halogens; benzyloxyethyl; benzyloxy-ethyl substituted by one or more halogens; or is —NRR; Ris hydrogen or lower alkyl; Ris lower alkyl; tetrahydropyran-4-yl; —CH-cycloalkyl; or cycloalkyl optionally substituted by lower alkyl substituted by one or more halogens; or Rand Rform together with the N-atom to which they are attached a heterocycloalkyl group with 4 or 5 carbon atoms, which is optionally substituted by one or more substituents selected from halogen; or lower alkyl substituted by one or more halogens; X is —CH—or —(CH)—; Ar is phenyl or pyridinyl; Ris halogen; lower alkyl; lower alkyl substituted by one or more halogens; or lower alkoxy; n is 1 or 2; or to a pharmaceutically active salt thereof, to a stereoisomeric form, including an individual diastereoisomer or enantiomer of the compound of formula (IA) as well as to a racemic or non-racemic mixture thereof. The present invention also relates to the use of a compound of formula (IA) for treating certain neurodegenerative disorders characterized by cytotoxic TAU misfolding and/or aggregation.